This paper describes and assesses pharmaceutical pricing and reimbursement policies in Canada, considering them in the context of the broader policy and market environment in which they operate, and investigating their role in contributing to Canada’s achievements in meeting a range of objectives relating to the pharmaceutical policy. The federal government regulates prices of patented pharmaceutical products with the objective of protecting consumers against excessive prices. Regulation has very likely been responsible for bringing Canada’s prices for patented medicines roughly in line with European comparators. Prices of generic products, which are not regulated, are relatively high although high...
Pharmaceutical Pricing and Reimbursement Policies in Canada
Working paper
OECD Health Working Papers
Share
Facebook
Twitter
LinkedIn
Abstract
In the same series
-
11 September 2024
-
14 August 2024
-
12 July 2024
Related publications
-
30 July 2024
-
Country note10 July 2024